Flag of the European Union EU Clinical Trials Register Help

Clinical trials for - Crohn’s Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,525 result(s) found for: - Crohn’s Disease. Displaying page 143 of 1,427.
    «« First « Previous 139  140  141  142  143  144  145  146  147  Next» Last»»
    EudraCT Number: 2011-000914-21 Sponsor Protocol Number: 161003 Start Date*: 2012-02-13
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE A...
    Medical condition: Mild to moderate Alzheimer’s disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021048-16 Sponsor Protocol Number: MOR-100 Start Date*: 2010-10-07
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)
    Medical condition: Mucopolysaccharidosis Type IVA
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10028095 Mucopolysaccharidosis IV PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001360-19 Sponsor Protocol Number: ADN011 Start Date*: 2016-01-04
    Sponsor Name:ADIENNE SA
    Full Title: Prospective, phase II/III, randomized clinical study to compare BEGEDINA® versus “conventional treatment” for treating steroid resistant acute graft-versus host disease
    Medical condition: steroid resistant acute graft versus host disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004155-32 Sponsor Protocol Number: 3090A1-301 Start Date*: 2015-04-06
    Sponsor Name:Wyeth Research
    Full Title: An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX ) in Children Less Than 6 Years of Age With Severe Hemophilia B
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005157-29 Sponsor Protocol Number: PHRR-04/PG/SPAXIM Start Date*: 2007-04-27
    Sponsor Name:CHRU-TOURS
    Full Title: EFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE
    Medical condition: Les patients seront traités par infliximab, avec ou sans méthotrexate associé, selon la pratique habituelle en accord avec le libellé de l’A.M.M. Seuls le nombre de prélèvements sanguins et de visi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002556 Ankylosing spondylitis LLT
    9.1 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004350-28 Sponsor Protocol Number: VEG20007 Start Date*: 2006-08-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or...
    Medical condition: Advanced or metastatic breast cancer with ErbB2 FISH postive tumours
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-002271-97 Sponsor Protocol Number: F901318C21 Start Date*: 2017-04-07
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of oral F901318 (combined with fluconazole and posaconazole) for antifungal prophylaxis in patients undergoing che...
    Medical condition: Invasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000907-27 Sponsor Protocol Number: D2782C00010 Start Date*: 2008-10-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Ur...
    Medical condition: Stage IV urothelial Cancer Cáncer de urotelio estadío 4
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001429-41 Sponsor Protocol Number: ML39568 Start Date*: 2017-12-20
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
    Full Title: “TOCIlizumab for difficult-to-treat RETroperitoneal fibrosis. TOCIRET Trial”
    Medical condition: idiopathic retroperitoneal fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10021244 Idiopathic retroperitoneal fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005449-19 Sponsor Protocol Number: Start Date*: 2013-04-24
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: A double-blind, randomised controlled trial of percutaneous transluminal angioplasty (PTA) & Ramipril versus PTA & placebo in the management of intermittent claudication (IC)
    Medical condition: Peripheral Arterial Disease: Intermittent Claudication
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10009241 Claudication intermittent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002613-31 Sponsor Protocol Number: 009896QM Start Date*: 2015-04-27
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
    Medical condition: Triple-Negative Breast Cancer Non-squamous Small Cell Lung Cancer Squamous Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-016826-15 Sponsor Protocol Number: BC 1.2.001 Start Date*: 2010-05-19
    Sponsor Name:CECOG
    Full Title: A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combina...
    Medical condition: metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) SI (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003910-42 Sponsor Protocol Number: UC-0150/1309_SARCOME_12 Start Date*: 2014-05-06
    Sponsor Name:UNICANCER
    Full Title: A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas.
    Medical condition: Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008736 Chondrosarcoma metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031294 Osteosarcoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004923-34 Sponsor Protocol Number: RSV-MVA-004 Start Date*: 2022-07-07
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults ≥60 Years of Age
    Medical condition: respiratory syncytial virus disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001079-18 Sponsor Protocol Number: FLT180a-06 Start Date*: 2022-04-27
    Sponsor Name:Freeline Therapeutics Ltd
    Full Title: A dose confirmation study of FLT180a (adeno-associated viral vector containing the Padua variant of a codon-optimized human Factor IX gene) in adult subjects with hemophilia B.
    Medical condition: Haemophilia B.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004621-24 Sponsor Protocol Number: IFCT-1904 Start Date*: 2020-11-18
    Sponsor Name:IFCT
    Full Title: A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
    Medical condition: BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    22.0 10022891 - Investigations 10075676 BRAF V600E mutation positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004730-34 Sponsor Protocol Number: 361.11 Start Date*: 2011-07-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: A phase II multicentre, randomized, controlled open-label study on the use of anti-thymocyte globulin and rituximab for immunomodulation of graft-versus-host disease in allogeneic matched transpla...
    Medical condition: graft-versus-host disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004892-41 Sponsor Protocol Number: VT-001-0050 Start Date*: 2021-07-13
    Sponsor Name:Vera Therapeutics, Inc.
    Full Title: A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003727-38 Sponsor Protocol Number: MEN1611-02 Start Date*: 2020-05-05
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: OPEN-LABEL, MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CA MUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EG...
    Medical condition: PIK3CA mutated colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001485-41 Sponsor Protocol Number: AMAD001 Start Date*: 2005-04-20
    Sponsor Name:Institute for Neurodegenerative Disorders
    Full Title: A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease
    Medical condition: Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see exclusionary criteria).
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 139  140  141  142  143  144  145  146  147  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 12 14:38:04 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA